New pill targets brain inflammation in Parkinson's – first human tests begin
Disease control
Recruiting now
This early-stage trial tests an experimental oral drug called HL-400 in 86 healthy volunteers. The drug aims to block a protein (NLRP3) linked to inflammation, which may play a role in Parkinson's disease. The study focuses on safety, tolerability, and how the drug moves through …
Phase: PHASE1 • Sponsor: Highlightll Pharmaceutical (USA) LLC • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC